Craft

Twist Bioscience

Stock Price

$42.7

2024-10-29

Market Capitalization

$2.5 B

2024-10-29

Revenue

$376.6 M

FY, 2025

Twist Bioscience Summary

Company Summary

Overview
Twist Bioscience is a synthetic biology company that develops a proprietary silicon-based manufacturing process for the production of synthetic DNA. It offers synthetic genes, tools for next-generation sample preparation, antibody libraries for drug discovery and development, oligo pools, and other products. The company also provides a semiconductor-based platform that miniaturizes the chemistry necessary for DNA synthesis. Twist Bioscience serves the medicine, agriculture, industrial chemicals, and data storage markets.
Type
Public
Status
Active
Founded
2013
HQ
South San Francisco, CA, US | view all locations
Website
https://www.twistbioscience.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Emily Leproust
  • Patrick Finn

    Patrick Finn, President and Chief Operating Officer

  • Adam Laponis

    Adam Laponis, Chief Financial Officer

    • Siyuan Chen

      Siyuan Chen, Chief Technology Officer

    Operating MetricsView all

    Customers

    2.9K
    31.8%

    FY, 2021

    Synthetic DNA Users

    100K

    FY, 2020

    Number of Genes Shipped

    372.3K
    10.0%

    FY, 2021

    LocationsView all

    8 locations detected

    • South San Francisco, CA HQ

      United States

      681 Gateway Blvd

    • Carlsbad, CA

      United States

      5909 Sea Otter Pl #210

    • Quincy, MA

      United States

      1250 Hancock St #210N

    • Wilsonville, OR

      United States

      26600 SW Parkway Ave

    • Guangzhou, Guangdong Province

      China

      Guangzhou International Bio-Island, #36 Huanyu Third Road, Guanzhou Life Science Innovation Center, North Tower, Second Floor, Room 203

    • Tel Aviv, Tel Aviv District

      Israel

      Menachem Begin 121

    and 2 others

    Twist Bioscience Financials

    Summary Financials

    Revenue (Q2, 2026)
    $110.7M
    Gross profit (Q2, 2026)
    $57.1M
    Net income (Q2, 2026)
    ($44.0M)
    Cash (Q2, 2026)
    $122.7M
    EBIT (Q2, 2026)
    ($45.9M)
    Enterprise value
    $2.5B

    Footer menu